2021
PO03 A Novel Design in Peripheral Channels of a Brachytherapy Multichannel Applicator Demonstrates Significant Differences in Dose to Surrounding Volume
Tien C, Damast S, Young M, Kaur M, Kim J, Chen Z. PO03 A Novel Design in Peripheral Channels of a Brachytherapy Multichannel Applicator Demonstrates Significant Differences in Dose to Surrounding Volume. Brachytherapy 2021, 20: s56-s57. DOI: 10.1016/j.brachy.2021.06.091.Peer-Reviewed Original ResearchMultichannel applicatorSignificant differences
2017
Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions
Tien CJ, Astrahan MA, Kim JM, Materin M, Chen Z, Nath R, Liu W. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions. Brachytherapy 2017, 16: 1057-1064. PMID: 28778599, DOI: 10.1016/j.brachy.2017.06.014.Peer-Reviewed Original ResearchConceptsEye modelDisc distanceDose differenceTumor apexPrescription doseOcular parametersPlaque SimulatorOcular structuresSubstantial dose differencesTarget volumePlaque positionDosimetric parametersPatientsClinical planningDosimetric impactSignificant differencesBrachytherapy planningSeed strengthPlaquesBrachytherapy dose distributionsDose distributionPatient-specific modelsDifferencesTumorsRetina
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer